Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD.

Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15.

PMID:
30770959
2.

A successful founder off the beaten path.

Hoerr I.

Nat Biotechnol. 2017 Oct 11;35(10):900-903. doi: 10.1038/nbt.3975. No abstract available.

PMID:
29019989
3.

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.

Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, Gottardo R, Bica MA, Garofano A, Koch SD, Fotin-Mleczek M, Hoerr I, Clemens R, von Sonnenburg F.

Lancet. 2017 Sep 23;390(10101):1511-1520. doi: 10.1016/S0140-6736(17)31665-3. Epub 2017 Jul 25.

PMID:
28754494
4.

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.

Hong HS, Koch SD, Scheel B, Gnad-Vogt U, Schröder A, Kallen KJ, Wiegand V, Backert L, Kohlbacher O, Hoerr I, Fotin-Mleczek M, Billingsley JM.

Oncoimmunology. 2016 Nov 18;5(12):e1249560. doi: 10.1080/2162402X.2016.1249560. eCollection 2016.

5.

Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.

Rittig SM, Haentschel M, Weimer KJ, Heine A, Müller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P.

Oncoimmunology. 2015 Oct 29;5(5):e1108511. doi: 10.1080/2162402X.2015.1108511. eCollection 2016 May.

6.

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.

Kübler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, Parmiani G, Hampel C, Wedel S, Trojan L, Jocham D, Maurer T, Rippin G, Fotin-Mleczek M, von der Mülbe F, Probst J, Hoerr I, Kallen KJ, Lander T, Stenzl A.

J Immunother Cancer. 2015 Jun 16;3:26. doi: 10.1186/s40425-015-0068-y. eCollection 2015.

7.

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P.

Mol Ther. 2011 May;19(5):990-9. doi: 10.1038/mt.2010.289. Epub 2010 Dec 28.

8.

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.

Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C.

J Immunother. 2009 Jun;32(5):498-507. doi: 10.1097/CJI.0b013e3181a00068.

PMID:
19609242
9.

Results of the first phase I/II clinical vaccination trial with direct injection of mRNA.

Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S.

J Immunother. 2008 Feb-Mar;31(2):180-8. doi: 10.1097/CJI.0b013e31815ce501.

PMID:
18481387
10.

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent.

Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo S.

Gene Ther. 2007 Aug;14(15):1175-80. Epub 2007 May 3. Erratum in: Gene Ther. 2009 May;16(5):706.

PMID:
17476302
11.

Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA.

Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, Weller M, Pascolo S.

Eur J Immunol. 2006 Oct;36(10):2807-16.

12.

Characterization of the ribonuclease activity on the skin surface.

Probst J, Brechtel S, Scheel B, Hoerr I, Jung G, Rammensee HG, Pascolo S.

Genet Vaccines Ther. 2006 May 29;4:4.

13.

Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.

Carralot JP, Weide B, Schoor O, Probst J, Scheel B, Teufel R, Hoerr I, Garbe C, Rammensee HG, Pascolo S.

Genet Vaccines Ther. 2005 Aug 22;3:6.

14.

Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro.

Teufel R, Carralot JP, Scheel B, Probst J, Walter S, Jung G, Hoerr I, Rammensee HG, Pascolo S.

Cell Mol Life Sci. 2005 Aug;62(15):1755-62.

PMID:
16003494
15.

Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA.

Scheel B, Teufel R, Probst J, Carralot JP, Geginat J, Radsak M, Jarrossay D, Wagner H, Jung G, Rammensee HG, Hoerr I, Pascolo S.

Eur J Immunol. 2005 May;35(5):1557-66.

16.

Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines.

Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G, Rammensee HG, Pascolo S.

Cell Mol Life Sci. 2004 Sep;61(18):2418-24.

PMID:
15378210
17.

In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.

Hoerr I, Obst R, Rammensee HG, Jung G.

Eur J Immunol. 2000 Jan;30(1):1-7.

Supplemental Content

Support Center